Trodelvy 180 mg vial | Indian Pharma Network - PowerPoint PPT Presentation

About This Presentation
Title:

Trodelvy 180 mg vial | Indian Pharma Network

Description:

Healthcare professionals recommend using the drug Sacituzumab govitecan-hziy to treat patients with unresectable locally advanced or metastatic triple-negative breast cancer and locally advanced or metastatic urothelial cancer. Trodelvy 180 mg vial for single-dose is used for intravenous administration. Before each dose of Trodelvy, premedication for the prevention of infusion reactions and prevention of chemotherapy-induced nausea and vomiting (CINV) is recommended. Premedicate with antipyretics, H1 and H2 blockers before infusion and corticosteroids may be used for patients with prior infusion reactions. Premedicate with a two or three-drug combination regimen. – PowerPoint PPT presentation

Number of Views:0
Slides: 3
Provided by: jhonpharma
Tags:

less

Transcript and Presenter's Notes

Title: Trodelvy 180 mg vial | Indian Pharma Network


1
Triple-Negative Breast Cancer And their Treatment
Breast cancer is a type of cancer in which cells
in the breast grow out of control. There are
different kinds of breast cancer. The kind of
breast cancer depends on which cells in the
breast turn into cancer. Normal breast cells have
receptors that respond to hormones such as
estrogen and progesterone, which allows them to
grow and regress in response to the hormone
level. Hormone receptors may or may not be
present in breast cancer. About two- thirds of
breast cancers are "positive" and contain these
receptors as normal breast cells do. HER2/neu
(hormone epidermal growth factor receptor 2) is a
protein molecule that has a role in cell
proliferation in normal cells. In some breast
cancers, this protein is overly produced or
"positive." For HER2-positive tumours, there is a
specific medication that targets this protein.
Triple-negative breast cancers are not positive
for estrogen receptors, progesterone receptors
or HER2 protein.
  • Signs and Symptoms
  • The signs and symptoms of Triple-negative breast
    cancer are
  • A new lump or mass
  • Swelling of all or part of a breast (even if no
    lump is felt)
  • Skin dimpling (sometimes looking like an orange
    peel)
  • Breast or nipple pain
  • Nipple retraction (turning inward)
  • Nipple or breast skin that is red, dry, flaking,
    or thickened
  • Nipple discharge (other than breast milk)
  • Swollen lymph nodes under the arm or near the
    collarbone (This can be a sign of breast cancer
    spreading even before the original tumour in the
    breast is large enough to be felt.)
  • Note Many of these symptoms can also be caused
    by non-cancerous breast conditions. Still, it's
    essential to have any new breast mass, lump, or
    other change checked by an experienced
    healthcare professional so the cause can be found
    and treated if needed.

2
Treatment for Triple-negative breast
cancer Chemotherapy Cells from the cancerous
lump may have spread somewhere else in your
body. The goal of chemotherapy is to kill those
cancer cells wherever they may be. Chemotherapy
lowers the chance that your cancer will grow or
come back. Surgery In surgery, the surgeon
removes the breast and nearby lymph nodes to see
if cancer has spread. Radiation therapy In
such therapies, high-energy radiation is given to
your breast to kill any remaining cancer
cells. Medication There are medications for
triple-negative breast cancer treatment, such
as polymerase inhibitors or PARP inhibitors and
immunotherapy medications, such as Trodelvy 180
mg injection, which contains Trodelvy is a type
of drug called an antibody-drug conjugate (ADC).
It consists of an antibody (an immune system
protein) that's linked to a chemotherapy drug.
This medicine contains Sacituzumab govitecan hziy.
Statistics Triple-negative breast cancer in
India and world
In the USA, according to the American Cancer
Society Journals, a total of 1,151,724 breast
cancer cases from 2010 through 2014 in the 39
states were identified in the data set, with a
mean case age at diagnosis of 61.8 years. In this
comprehensive collection of breast cancer cases,
approximately 75 of the patients were NHW women
among all races/ethnicities, approximately 27.7
were diagnosed at a late stage, and around 5
were diagnosed at a distant stage. In the
examined time period, TNBC cases accounted for
8.4 of all breast cancer cases. In India,
according to the National Center for
Biotechnology Information (NIH), seventeen
cross-sectional studies involving 7,237 patients
with breast cancer were included in the review
of analysis made by NIH.14-30 Mean age of
patients ranged from 43 to 55 years across
studies, with a weighted average of age 50
years. Source - https//www.indianpharmanetwork.
in/triple-negative-breast-cancer-and-their-treatme
nt/
Write a Comment
User Comments (0)
About PowerShow.com